318 related articles for article (PubMed ID: 26997242)
1. High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis.
Hoffmann-Vold AM; Tennøe AH; Garen T; Midtvedt Ø; Abraityte A; Aaløkken TM; Lund MB; Brunborg C; Aukrust P; Ueland T; Molberg Ø
Chest; 2016 Aug; 150(2):299-306. PubMed ID: 26997242
[TBL] [Abstract][Full Text] [Related]
2. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.
Hoffmann-Vold AM; Aaløkken TM; Lund MB; Garen T; Midtvedt Ø; Brunborg C; Gran JT; Molberg Ø
Arthritis Rheumatol; 2015 May; 67(8):2205-12. PubMed ID: 25916462
[TBL] [Abstract][Full Text] [Related]
4. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
[TBL] [Abstract][Full Text] [Related]
5. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.
Zhang XJ; Bonner A; Hudson M; ; Baron M; Pope J
J Rheumatol; 2013 Jun; 40(6):850-8. PubMed ID: 23547215
[TBL] [Abstract][Full Text] [Related]
6. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?
Elhaj M; Charles J; Pedroza C; Liu X; Zhou X; Estrada-Y-Martin RM; Gonzalez EB; Lewis DE; Draeger HT; Kim S; Arnett FC; Mayes MD; Assassi S
J Rheumatol; 2013 Jul; 40(7):1114-20. PubMed ID: 23588945
[TBL] [Abstract][Full Text] [Related]
7. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
[TBL] [Abstract][Full Text] [Related]
9. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
[TBL] [Abstract][Full Text] [Related]
10. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
12. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.
Prasse A; Pechkovsky DV; Toews GB; Schäfer M; Eggeling S; Ludwig C; Germann M; Kollert F; Zissel G; Müller-Quernheim J
Arthritis Rheum; 2007 May; 56(5):1685-93. PubMed ID: 17469163
[TBL] [Abstract][Full Text] [Related]
13. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody.
Guillen-Del Castillo A; Pilar Simeón-Aznar C; Fonollosa-Pla V; Alonso-Vila S; Reverte-Vinaixa MM; Muñoz X; Pallisa E; Selva-O'allaghan A; Fernández-Codina A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2014 Dec; 44(3):331-7. PubMed ID: 25110305
[TBL] [Abstract][Full Text] [Related]
14. Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis.
Ryerson CJ; O'Connor D; Dunne JV; Schooley F; Hague CJ; Murphy D; Leipsic J; Wilcox PG
Chest; 2015 Nov; 148(5):1268-1275. PubMed ID: 25996795
[TBL] [Abstract][Full Text] [Related]
15. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis.
Tiev KP; Hua-Huy T; Kettaneh A; Gain M; Duong-Quy S; Tolédano C; Cabane J; Dinh-Xuan AT
Eur Respir J; 2011 Dec; 38(6):1355-60. PubMed ID: 21778167
[TBL] [Abstract][Full Text] [Related]
16. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
Wu W; Jordan S; Becker MO; Dobrota R; Maurer B; Fretheim H; Ye S; Siegert E; Allanore Y; Hoffmann-Vold AM; Distler O
Ann Rheum Dis; 2018 Sep; 77(9):1326-1332. PubMed ID: 29875097
[TBL] [Abstract][Full Text] [Related]
17. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.
Khanna D; Tseng CH; Farmani N; Steen V; Furst DE; Clements PJ; Roth MD; Goldin J; Elashoff R; Seibold JR; Saggar R; Tashkin DP
Arthritis Rheum; 2011 Oct; 63(10):3078-85. PubMed ID: 21618205
[TBL] [Abstract][Full Text] [Related]
18. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort.
Hoffmann-Vold AM; Fretheim H; Halse AK; Seip M; Bitter H; Wallenius M; Garen T; Salberg A; Brunborg C; Midtvedt Ø; Lund MB; Aaløkken TM; Molberg Ø
Am J Respir Crit Care Med; 2019 Nov; 200(10):1258-1266. PubMed ID: 31310156
[No Abstract] [Full Text] [Related]
19. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
[TBL] [Abstract][Full Text] [Related]
20. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.
Guler SA; Kwan JM; Winstone TA; Milne KM; Dunne JV; Wilcox PG; Ryerson CJ
Respir Med; 2017 Aug; 129():1-7. PubMed ID: 28732817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
